Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy

Expert Review of Clinical Pharmacology

Volumn 9, Issue 1, 2016, Pages 59-68

  Meehan, Cristina Adelia ^a   Cochran, Elaine ^a   Kassai, Andrea ^a   Brown, Rebecca J ^a   Gorden, Phillip ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

insulin resistance; leptin; lipodystrophy; metabolic syndrome; metreleptin

Indexed keywords

GLUCOSE; METRELEPTIN; NEUTRALIZING ANTIBODY; LEPTIN;

ABDOMINAL PAIN; ACQUIRED GENERALIZED LIPODYSTROPHY; ANAPHYLAXIS; CONGENITAL GENERALIZED LIPODYSTROPHY; DECREASED APPETITE; DIET RESTRICTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; LEPTIN DEFICIENCY; LIPID STORAGE; LIPODYSTROPHY; LIVER WEIGHT; META ANALYSIS (TOPIC); METABOLIC DISORDER; NONHUMAN; RASH; REVIEW; RODENT MODEL; SIDE EFFECT; TREATMENT RESPONSE; URTICARIA; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; DEFICIENCY; INJECTION; LIPODYSTROPHY, CONGENITAL GENERALIZED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

HUMANS; INJECTIONS; LEPTIN; LIPODYSTROPHY; LIPODYSTROPHY, CONGENITAL GENERALIZED; SEVERITY OF ILLNESS INDEX;

EID: 84949110073     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2016.1096772     Document Type: Review

References (51)

1. Garg A. Clinical review: lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011; 96 (11): 3313-3325
2. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004; 350 (12): 1220-1234
3. Wachslicht-Rodbard H., et al. Heterogeneity of the insulin-receptor interaction in lipoatropic diabetes. J Clin Endocrinol Metab. 1981; 52 (3): 416-425
4. Agarwal AK., et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab. 2003; 88 (10): 4840-4847
5. Speckman RA., et al. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. Am J Hum Genet. 2000; 66 (4): 1192-1198
6. Payne F., et al. Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease. Proc Natl Acad Sci U S A. 2014; 111 (24): 8901-8906
7. Javor ED., et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology. 2005; 41 (4): 753-760
8. Safar Zadeh E., et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol. 2013; 59 (1): 131-137
9. Arioglu E., et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 2000; 133 (4): 263-274
10. Zhang Y., et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372 (6505): 425-432
11. Coleman DL. A historical perspective on leptin. Nat Med. 2010; 16 (10): 1097-1099
12. Bluher S, Mantzoros CS. Leptin in humans: lessons from translational research. Am J Clin Nutr. 2009; 89 (3): 991S-997S.
13. Frederich RC., et al. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med. 1995; 1 (12): 1311-1314
14. Ahima RS., et al. Role of leptin in the neuroendocrine response to fasting. Nature. 1996; 382 (6588): 250-252
15. Minocci A., et al. Leptin plasma concentrations are dependent on body fat distribution in obese patients. Int J Obes Relat Metab Disord. 2000; 24 (9): 1139-1144
16. Moon HS., et al. Leptins role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev. 2013; 34 (3): 377-412
17. Gorden P., et al. Is there a human model for the metabolic syndrome with a defined aetiology? Diabetologia. 2010; 53 (7): 1534-1536
18. Heymsfield SB., et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999; 282 (16): 1568-1575
19. Farooqi IS., et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002; 110 (8): 1093-1103
20. Paz-Filho G, Delibasi T, Erol HK., et al. Congenital leptin deficiency and thyroid function. Thyroid Res. 2009; 2 (1): 11
21. Oral EA., et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002; 346 (8): 570-578
22. Javor ED., et al. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes. 2005; 54 (7): 1994-2002
23. Chong AY., et al. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2010; 53 (1): 27-35
24. Diker-Cohen T., et al. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab. 2015; 100 (5): 1802-1810
25. Rodriguez AJ., et al. Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-Analysis into the effects of leptin on metabolic and hepatic endpoints. Arq Bras Endocrinol Metabol. 2014; 58 (8): 783-797
26. McDuffie JR., et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab. 2004; 89 (9): 4258-4263
27. Moran SA., et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism. 2004; 53 (4): 513-519
28. Petersen KF., et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002; 109 (10): 1345-1350
29. Lungu AO., et al. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2012; 97 (2): 563-567
30. Joseph J., et al. Lipid regulation in lipodystrophy versus the obesity-Associated metabolic syndrome: the dissociation of HDL-C and triglycerides. J Clin Endocrinol Metab. 2014; 99 (9): E1676-80
31. Javor ED., et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab. 2004; 89 (7): 3199-3207
32. Musso C., et al. Spectrum of renal diseases associated with extreme forms of insulin resistance. Clin J Am Soc Nephrol. 2006; 1 (4): 616-622
33. Ebihara K., et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2007; 92 (2): 532-541
34. Ebihara K, Masuzaki H, Nakao K. Long-term leptin-replacement therapy for lipoatrophic diabetes. N Engl J Med. 2004; 351 (6): 615-616
35. Maguire M., et al. Pregnancy in a woman with congenital generalized lipodystrophy: leptins vital role in reproduction. Obstet Gynecol. 2012; 119 (2 Pt 2): 452-455.
36. Brown RJ., et al. Lymphoma in acquired generalized lipodystrophy. Leuk Lymphoma. 2015; 1-6. PMD 25864863
37. Strong AL., et al. Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers. Breast Cancer Res. 2015; 17: 112
38. Shimomura I., et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999; 401 (6748): 73-76
39. Simonds SE., et al. Leptin mediates the increase in blood pressure associated with obesity. Cell. 2014; 159 (6): 1404-1416
40. Brown RJ, Meehan CA, Gorden P. Leptin does not mediate hypertension associated with human obesity. Cell. 2015; 162: 465-466
41. Reitman ML. Leptin in the liver: a toxic or beneficial mix? Cell Metab. 2012; 16 (1): 1-2
42. Imajo K., et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab. 2012; 16 (1): 44-54
43. Oral EA., et al. Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy. J Clin Endocrinol Metab. 2006; 91 (2): 621-628
44. Christensen JD., et al. Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J Clin Endocrinol Metab. 2014; 99 (8): E1493-500
45. Farooqi IS., et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999; 341 (12): 879-884
46. Paz-Filho G, Mastronardi CA, Licinio J. Leptin treatment: facts and expectations. Metabolism. 2015; 64 (1): 146-156
47. Brown RJ, Cochran E, Gorden P. Metreleptin improves blood glucose in patients with insulin receptor mutations. J Clin Endocrinol Metab. 2013; 98 (11): E1749-E1756
48. Tsoukas MA, Farr OM, Mantzoros CS. Leptin in congenital and HIV-Associated lipodystrophy. Metabolism. 2015; 64 (1): 47-59
49. Chan JL, Mantzoros CS. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhea and anorexia nervosa. Lancet. 2005; 366 (9479): 74-85
50. Wang MY., et al. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci U S A. 2010; 107 (11): 4813-4819
51. Gaudet D., et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014; 371 (23): 2200-2206